eligibility_summary
Eligibility: consent, CD19/CD22/BCMA+ hematologic malignancy, age 15–80, relapsed/refractory after ≥1 standard+1 salvage, persistent MRD, or post‑HSCT relapse, ECOG 0–3, LVEF ≥50%, creatinine ≤1.5 mg/dL, ALT/AST ≤2.5×ULN, bilirubin ≤1.5 mg/dL, survival ≥12 wks. Exclude: major heart disease/QTc>480 ms, active GVHD/immunosuppression, recent other cancers, active infection, HBV/HCV/HIV/CMV/syphilis+, recent trial, severe allergy, unstable disease, pregnancy/lactation or plans within 2 yrs, any high‑risk condition.
trial_source
clinical_trials.gov from Dec 2, 2025
annotation_status
ai
ai_summary
Intervention: Autologous chimeric antigen receptor T cells (CAR‑T) engineered to co‑express interleukin‑15 (IL‑15), type: gene‑modified cellular immunotherapy/adoptive cell transfer. Mechanism: CAR‑T cells bind disease‑specific B‑cell antigens (CD19 and/or CD22 for B‑ALL/B‑NHL, BCMA for multiple myeloma), trigger CAR (CD3ζ‑mediated) activation and cytotoxicity (perforin/granzymes) to lyse tumor cells. IL‑15 co‑expression provides autocrine IL‑15Rγ/JAK‑STAT5 signaling that enhances T‑cell activation, proliferation, survival, and persistence, potentially reducing exhaustion. Targets: malignant B lymphoblasts, B‑cell lymphoma cells, and myeloma plasma cells, key pathways: CD19/CD22/BCMA antigen recognition, CAR‑T activation, and IL‑15 cytokine signaling.